Subscribe To
Harpoon therapeutics stock soars on ‘promising' lung cancer drug results
Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that it...
October 23, 2023, 9:32 am
The dividend investor's natural gas export playbook - part 3
Multiple natural gas export terminals are set to begin operations, increasing LNG exports from 14 BCF/d to over 26.5 BCF/day by 2030. Projects under c...
October 23, 2023, 9:09 am
Bt, unilever among firms calling for more from cop28
BT Group PLC (LSE:BT.A) and Unilever PLC (LSE:ULVR) are among firms which have called on world leaders to rework policies to support the phase-out of ...
October 23, 2023, 7:52 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Roche enters into a definitive agreement to acquire telavant including rights to novel tl1a directed antibody (rvt-3101) for the treatment of inflammatory bowel disease from roivant
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and ...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Cvr partners: an excellent dividend but it is worth waiting
CVR Partners is a young MLP company operating in the fertilizer sector with two large production plants. The company's profitability and dividend are ...
October 22, 2023, 11:02 pm
Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...
October 22, 2023, 6:59 pm
Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc
– Data presented at the European Society for Medical Oncology from the phase 1/2 trial with bavdegalu...
October 22, 2023, 11:00 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
